Tolerance Bio Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$15.1M
- Investors
-
7
Tolerance Bio General Information
Description
Developer of therapies designed to extend health span by preserving, restoring, and modulating thymic function. The company offers approaches targeting immune tolerance regulation, thymic function modulation techniques, enabling healthcare providers and patients to improve immune system balance and support long-term health outcomes.
Contact Information
Website
www.tolerancebio.comCorporate Office
- 2929 Arch Street
- 4th Floor
- Philadelphia, PA 19104
- United States
Corporate Office
- 2929 Arch Street
- 4th Floor
- Philadelphia, PA 19104
- United States
Tolerance Bio Timeline
Tolerance Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 03-Jun-2026 | $15.1M | Completed | Generating Revenue | ||
| 1. Seed Round | 10-Oct-2024 | Completed | Generating Revenue |
Tolerance Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-3 | ||||||||
| Seed-2 | ||||||||
| Seed | 4,561,713 | $0.000010 | $2.67 | $2.67 | 1x | $2.67 | 16.43% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Tolerance Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tolerance Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tolerance Bio Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ben Franklin Technology Partners of Southeastern Pennsylvania | Accelerator/Incubator | Minority | ||
| BioAdvance Capital (Conshohocken) | Venture Capital | Minority | ||
| Caixa Capital Risc | Corporate Venture Capital | Minority | ||
| Columbus Venture Partners | Venture Capital | Minority | ||
| Criteria Bio Ventures | Venture Capital | Minority |
Tolerance Bio FAQs
-
When was Tolerance Bio founded?
Tolerance Bio was founded in 2023.
-
Where is Tolerance Bio headquartered?
Tolerance Bio is headquartered in Philadelphia, PA.
-
What is the size of Tolerance Bio?
Tolerance Bio has 10 total employees.
-
What industry is Tolerance Bio in?
Tolerance Bio’s primary industry is Biotechnology.
-
Is Tolerance Bio a private or public company?
Tolerance Bio is a Private company.
-
What is the current valuation of Tolerance Bio?
The current valuation of Tolerance Bio is .
-
What is Tolerance Bio’s current revenue?
The current revenue for Tolerance Bio is .
-
How much funding has Tolerance Bio raised over time?
Tolerance Bio has raised $35.3M.
-
Who are Tolerance Bio’s investors?
Ben Franklin Technology Partners of Southeastern Pennsylvania, BioAdvance Capital (Conshohocken), Caixa Capital Risc, Columbus Venture Partners, and Criteria Bio Ventures are 5 of 7 investors who have invested in Tolerance Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
